Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FYX42
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $141,974
Award facts
- Contract value 100% obligated
- $141,973.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at approximately $142,000 by the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 16, 2025, and was awarded on August 25, 2025, without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million contract vehicle valid through November 2026 that authorizes the issuance of delivery orders for a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities worldwide.
XOLAIR (omalizumab) is a monoclonal antibody medication primarily used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria. As a specialized biologic pharmaceutical, its procurement through the DLA supply chain ensures availability for military beneficiaries and federal healthcare systems. DMS Pharmaceutical Group's established role as a key supplier within the federal pharmaceutical distribution network positions it to deliver this injectable medication efficiently to military medical facilities. The firm fixed-price structure and specified delivery location in Park Ridge, Illinois, reflect the streamlined procurement approach utilized under the DLA's framework agreement for routine pharmaceutical supply replenishment.
Quick answers
Who was awarded contract SPE2DB25FYX42?
SPE2DB25FYX42 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 25, 2025.
How much is contract SPE2DB25FYX42 worth?
The government has obligated $141,974 on SPE2DB25FYX42.
Is contract SPE2DB25FYX42 an order under another contract?
Yes. SPE2DB25FYX42 is a delivery order under SPE2DB22D9133, an indefinite delivery contract.
Was contract SPE2DB25FYX42 competed?
The extent of competition for SPE2DB25FYX42 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award